TRDA
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) has 9 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: May 21, 2026.
The most active filer is Chief Financial Officer WENTWORTH KORY JAMES with 4 filings. Insiders have net sold $1.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Dipal Doshi
- Employees:183
- HQ:Boston, MA, US
- IPO:2021-10-29
Insider Buying
$29K
reported purchases (SEC code P)
Insider Selling
$1.2M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$263.6M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Zeiher Bernhardt GFirst filing | Director | Purchase | 5,000 | $29K | May 21 | SEC ↗ |
Sethuraman NatarajanFirst filing | President, Research & Develop. | Sale | 25,907 | $399K | May 4 | SEC ↗ |
| President & COO | Sale | 15,000 | $230K | May 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,500 | $32K | Apr 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 5,089 | $66K | Mar 11 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,388 | $148K | Mar 11 | SEC ↗ | |
Dowden Nathan JFirst filing | President & COO | Sale | 3,116 | $41K | Mar 11 | SEC ↗ |
Dowden Nathan JFirst filing | President & COO | Sale | 11,894 | $155K | Mar 11 | SEC ↗ |
WENTWORTH KORY JAMESFirst filing | Chief Financial Officer | Sale | 7,988 | $98K | Mar 6 | SEC ↗ |
Related companies
Entrada Therapeutics, Inc. is in the Healthcare sector.